Table 3 Association of lymphatic vessel invasion with clinical criteria

Age

<40

2 (7.1)

2 (7.1)

1.0

4 (14.8)

0 (0)

0.012

4 (10.5)

0 (0)

0.065

≥40

26 (92.9)

26 (92.9)

23 (85.2)

30 (100)

34 (89.5)

19 (100)

Tumor size

<30

7 (25)

4 (14.8)

0.548

4 (14.8)

7 (25)

0.636

9 (23.7)

2 (11.8)

0.497

30 ≤ × < 60

12 (42.9)

15 (55.6)

14 (51.9)

13 (46.4)

17 (44.7)

10 (58.8)

60 ≥

9 (32.1)

8 (29.6)

9 (33.3)

8 (28.6)

12 (31.6)

5 (29.4)

Grade

I

3 (10.7)

7 (25.0)

0.387

5 (18.5)

5 (17.2)

0.197

5 (13.2)

5 (27.8)

0.607

II

14 (50.0)

13 (46.4)

15 (55.6)

12 (41.4)

19 (50)

8 (44.4)

III

10 (35.7)

6 (21.4)

7 (25.9)

9 (31.0)

12 (31.6)

4 (22.2)

No grade

1 (3.33)

2 (7.1)

0

3 (10.3)

2 (5.3)

1 (5.6)

Distant metastasis

Yes

9 (32.1)

6 (21.4)

0.432

7 (25.9)

8 (26.7)

0.05

11 (28.9)

4 (21.1

0.607

No

18 (64.3)

19 (67.9)

20 (74.1)

18 (60.0)

25 (65.8)

13 (68.4)

Not determine

1 (3.6)

3 (10.7)

0

4 (13.3)

2 (5.3)

2 (10.5)

Recurrence

No

26 (92.9)

28 (100)

0.92

27 (100)

28 (93.3)

0.105

36 (94.7)

19 (100)

0.198

Yes

2 (7.1)

0

0

2 (6.7)

2 (5.3)

0

ER

Positive

16 (59.3)

15 (55.6)

0.632

15 (57.7)

17 (58.6)

0.944

21 (56.8)

11 (61.1)

0.738

Negative

11 (40.7)

12 (44.4)

11 (42.3)

2 (41.4)

16 (43.2)

7 (38.9)

PR

Positive

13 (46.4)

14 (51.9)

0.687

13 (48.1)

15 (51.7)

0.789

17 (44.7)

11 (61.1)

0.251

Negative

15 (53.6)

13 (48.1)

14 (51.9)

14 (48.3)

21 (55.3)

7 (38.9)

Lymph nodes involvement

0

10 (37.0)

9 (32.1)

0.983

7 (25.9)

12 (41.4)

0.088

13 (35.1)

6 (31.6)

0.763

1

3 (11.1)

3 (10.7)

1 (3.7)

5 (17.2)

3 (8.1)

3 (15.8)

2 to 4

7 (25.9)

8 (28.6)

11 (40.7)

5 (17.2)

10 (27)

6 (31.6)

>4

7 (25.9)

8 (28.6)

8 (29.6)

7 (24.1)

11 (29.7)

4 (21.1)